Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Benefits of interferon-ß and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.

Benefits of interferon-ß and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer. 2011 Apr 15; 117(8):1721-30.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.